{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:04:27Z","timestamp":1775005467241,"version":"3.50.1"},"reference-count":7,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Transl Myol"],"abstract":"<jats:p>I was interested to read the article by Dowling et al.1 in the European Journal of Translational Myology, where the authors provide a comprehensive review of serum biomarkers for Duchenne Muscular Dystrophy (DMD), a devastating early-onset muscle wasting disease. The emphasis of research on liquid biopsy-based approaches, with the application of Mass Spectrometry (MS)-based proteomics for the identification of novel biomarkers like carbonic anhydrase CA3, fatty acid binding protein FABP3, and titin fragments, represents a revolutionary step towards minimally invasive diagnostics. As a neurologist and clinical pharmacologist working in Uganda, where diagnosis of DMD is delayed owing to the limited access to invasive tests, I find the prospects of these biofluid-based markers not only intriguing but also of immense worth in advancing precision medicine in resource-poor settings. [...]<\/jats:p>","DOI":"10.4081\/ejtm.2025.14257","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:00:11Z","timestamp":1760104811000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum biomarkers in Duchenne muscular dystrophy: a leap toward precision diagnostics"],"prefix":"10.4081","volume":"36","author":[{"given":"Daniel","family":"Matovu","sequence":"first","affiliation":[{"name":"Department of Neurology and Clinical Pharmacology, Kabale University School of Medicine, Kabale"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"198227","doi-asserted-by":"crossref","unstructured":"1. Dowling P, Negroni E, Trollet C, et al. Serum protein biomarker signature of Duchenne muscular dystrophy. Eur J Transl Myol 2025;35:13956.","DOI":"10.4081\/ejtm.2025.13956"},{"key":"198228","doi-asserted-by":"crossref","unstructured":"2. Hathout Y, Seol H, Han MH, et al. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Orphanet J Rare Dis 2016; 11:9.","DOI":"10.1186\/s12014-016-9109-x"},{"key":"198229","unstructured":"3. McNally EM, Mann DL, Pinto Y, et al. Dystrophin-glycoprotein complex and heart failure in Duchenne muscular dystrophy. Nat Rev Cardiol 2021;18:93\u2013108."},{"key":"198230","doi-asserted-by":"crossref","unstructured":"4. Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: viltolarsen for treatment of Duchenne muscular dystrophy. Nucleic Acid Ther 2020;30:272\u20136.","DOI":"10.1089\/nat.2020.0845"},{"key":"198231","doi-asserted-by":"crossref","unstructured":"5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251\u201367.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"198232","unstructured":"6. Turgeman T, Rosenberg T, Klein A, et al. Anti-fibrotic therapies for Duchenne muscular dystrophy. Matrix Biol 2023;119:133\u201347."},{"key":"198233","doi-asserted-by":"crossref","unstructured":"7. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7. micro-dystrophin in boys with Duchenne muscular dystrophy. JAMA Neurol 2020;77:1122\u201331.","DOI":"10.1001\/jamaneurol.2020.1484"}],"container-title":["European Journal of Translational Myology"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/download\/14257\/13458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/download\/14257\/13458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:01:58Z","timestamp":1775001718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/view\/14257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.4081\/ejtm.2025.14257","relation":{},"ISSN":["2037-7460","2037-7452"],"issn-type":[{"value":"2037-7460","type":"electronic"},{"value":"2037-7452","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}